HIF1A and cancer: By conjugating the clinically relevant EZN2968, anantisense oligonucleotide (ASO) that targets hypoxia inducible factor1-α (HIF-1-α) mRNA to the ND,33 we demonstrated avid in vitro uptake along withreduction in HIF-1-α transcript levels and a marked decreasein cell viability of cancer cells that are HIF-1-α dependent.We used this specific ASO because of the role of HIF-1-α inpromoting the survival of cancerous and tumorous tissue.